The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
The importance of adherence in tuberculosis treatment clinical trials and its relevance in explanatory and pragmatic trials
Open accessAbstract
Points• Adherence to prescribed treatment remains a critical component of clinical trials in tuberculosis (TB) treatment.Recent evidence indicates that adherence strongly influences the outcome of therapy; attention to its quantification and measures to assure its implementation should increase.• In the context of a World Health Organization (WHO) Technical Consultation on "Advances in Clinical Trial Design for Development of New TB Treatments," we reviewed the challenges related to adherence confronting the trials community.• We discuss the importance of adherence to therapy in TB clinical trials, consider several definitions and measures of adherence, comment on the standard provided by directly observed therapy (DOT), and briefly review evolving electronic methods for the assessment of adherence.• Adherence affects both the outcome of therapy and the risk of acquired drug resistance.Assessment of adherence should consider not only overall adherence but also the timing and intensity of nonadherence.• Appropriate methods for pooling and analyzing electronic data on adherence are needed.• Better methods are needed for linking information on adherence to individual pharmacokinetics and pharmacodynamics and to individual patient outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Treatment adherence is related to drug pharmacokinetics that causes a lower peak drug concentration than normal; in contrast, additional doses may result in a higher risk of toxicity than usual peak concentrations.30”
From The effects of acceptance and commitment therapy on psychosocial impact and adherence of multidrug-resistant tuberculosis patients (2022) · cites this paper as [30]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Piaggio, G., Elbourne, D. R., Pocock, S. J., Evans, S. J. W., Altman, D. G., & CONSORT Group, F. T. (2012) · JAMA · doi:10.1001/jama.2012.87802 · Cited by 2,428
Nahid, P., Dorman, S. E., Alipanah, N., Barry, P. M., Brożek, J., Cattamanchi, A., Chaisson, L. H., Chaisson, R. E., Daley, C. L., Grzemska, M., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw376 · Cited by 1,542
Self-citationFox, W., Ellard, G. A., & MITCHISON, D. A. (1999) · PubMed · Cited by 676
The Coronary Drug Project Research Group (1980) · New England Journal of Medicine · doi:10.1056/nejm198010303031804 · Cited by 659
Directly observed therapy for treating tuberculosis
Karumbi, J., & Garner, P. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003343.pub4 · Cited by 646
Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis
Gillespie, S. H., Crook, A. M., McHugh, T. D., Mendel, C. M., Meredith, S. K., Murray, S. R., Pappas, F., Phillips, P. P. J., & Nunn, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407426 · Cited by 644
The Effect of Directly Observed Therapy on the Rates of Drug Resistance and Relapse in Tuberculosis
Weis, S. E., Slocum, P. C., Blais, F. X., King, B., Nunn, M., Matney, G. B., Gomez, E., & FORESMAN, B. H. (1994) · New England Journal of Medicine · doi:10.1056/nejm199404283301702 · Cited by 588
Alipanah, N., Jarlsberg, L., Miller, C., Linh, N. N., Falzon, D., Jaramillo, E., & Nahid, P. (2018) · PLOS Medicine · doi:10.1371/journal.pmed.1002595 · Cited by 503
Self-citationWhen Tuberculosis Treatment Fails: A Social Behavioral Account of Patient Adherence
Sumartojo, E. (1993) · American Review of Respiratory Disease · doi:10.1164/ajrccm/147.5.1311 · Cited by 463
Blaschke, T. F., Osterberg, L. G., Vrijens, B., & Urquhart, J. (2011) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011711-113247 · Cited by 420
Research works printed but not linked: 5
- NYC Bureau of Tuberculosis Control, 2008, Clinical Policies and Protocols, 66
- HR Stagg, 2018, How do tuberculosis patients really take their treatment?, A detailed quantitative approach, 22, S171
- S Huan, 2012, Operational feasibility of medication monitors in monitoring treatment adherence among patients, Chin J Antituberculosis, 34, 419
- Thomas B, Kumar V, Chiranjeevi M, Ramachandran G, Murugesan P, Khandelwale AS, et al. Evaluating the accuracy of 99DOTS, a cellphone-based strategy for monitoring TB treatment adherence [Abstract PS18-588-26]. In: 49th Union World Conference on Lung Health, 2018 Oct 26, The Hague, The Netherlands.
- World Health Organization, 2018, Report of the Technical Consultation on Advances in Clinical Trial Design for Development of New TB Treatments, Glion-sur-Montreux, Switzerland, 14–16 March 2018
Cited by
Sorted by citations
Treatment Strategy for Rifampin-Susceptible Tuberculosis
Paton, N. I., Cousins, C., Suresh, C., Burhan, E., Chew, K. L., Dalay, V. B., Lu, Q., Kusmiati, T., Balanag, V. M., Lee, S. L., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212537 · Cited by 153
Sazali, M. F., Rahim, S. S. S. A., Mohammad, A. H., Kadir, F. B. M., Payus, A. O., Avoi, R., Jeffree, M. S., Omar, A., Ibrahim, M. Y., Atil, A., et al. (2023) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2022.0148 · Cited by 95
Pandolfo, A. M., Horne, R., Jani, Y. H., Reader, T. W., Bidad, N., Brealey, D. A., Enne, V. I., Livermore, D. M., Gant, V. A., & Brett, S. J. (2021) · BMJ Quality & Safety · doi:10.1136/bmjqs-2020-012479 · Cited by 83
Liu, X., Thompson, J., Dong, H., Sweeney, S., Li, X., Yuan, Y., Wang, X., He, W., Thomas, B., Xu, C., et al. (2023) · The Lancet Global Health · doi:10.1016/s2214-109x(23)00068-2 · Cited by 69
Self-citationRecent Progress and Challenges for Drug-Resistant Tuberculosis Treatment
Stephanie, F., Saragih, M., & Tambunan, U. S. F. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050592 · Cited by 65
Adisa, R., Ayandokun, T. T., & Ige, O. M. (2021) · BMC Public Health · doi:10.1186/s12889-021-10698-9 · Cited by 51
Digital Health Interventions to Enhance Tuberculosis Treatment Adherence: Scoping Review
Lee, S., Rajaguru, V., Baek, J. S., Shin, J., & Park, Y. (2023) · JMIR mhealth and uhealth · doi:10.2196/49741 · Cited by 57
Ernest, J. P., Strydom, N., Wang, Q., Zhang, N., Nuermberger, E. L., Dartois, V. A., & Savić, R. M. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-030920-011143 · Cited by 46
All nonadherence is equal but is some more equal than others? Tuberculosis in the digital era
Stagg, H. R., Flook, M., Martinecz, A., Kielmann, K., Wiesch, P. A. Z., Karat, A. S., Lipman, M. C. I., Sloan, D. J., Walker, E. F., & Fielding, K. (2020) · ERJ Open Research · doi:10.1183/23120541.00315-2020 · Cited by 35
Self-citationTadesse, A. W., Mohammed, Z., Foster, N., Quaife, M., McQuaid, C. F., Levy, J., van Kalmthout, K., van Rest, J., Jerene, D., Abdurhman, T., et al. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06833-x · Cited by 37
Self-citationAdvances in clinical trial design: Weaving tomorrow’s TB treatments
Lienhardt, C., Nunn, A., Chaisson, R. E., Vernon, A. A., Zignol, M., Nahid, P., Delaporte, É., & Kasaeva, T. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003059 · Cited by 34
Self-citationReal-world implementation of video-observed therapy in an urban TB program in the United States
Perry, A., Chitnis, A. S., Chin, A., Hoffmann, C. J., Chang, L. W., Robinson, M. L., Maltas, G., Munk, E., & Shah, M. (2021) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.21.0170 · Cited by 30
Shringarpure, K. S., Gurumurthy, M., Sagili, K. D., Taylor, M., Garner, P., Tonsing, J., Rao, R., & Sachdeva, K. S. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-063926 · Cited by 28
Target regimen profiles for tuberculosis treatment
Lienhardt, C., Dooley, K. E., Nahid, P., Wells, C. D., Ryckman, T. S., Kendall, E. A., Davies, G., Brigden, G., Churchyard, G., Cirillo, D. M., et al. (2024) · Bulletin of the World Health Organization · doi:10.2471/blt.24.291881 · Cited by 28
Self-citationZelnick, J., Daftary, A., Hwang, C., Labar, A. S., Boodhram, R., Maharaj, B., Wolf, A., Mondal, S., Amico, K. R., Orrell, C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1557 · Cited by 27
Ammari, L., Berriche, A., Kooli, I., Marrakchi, W., & Chakroun, M. (2022) · Medical radiology · doi:10.1007/978-3-031-07040-2_1 · Cited by 25
Elucidating the Antimycobacterial Mechanism of Action of Ciprofloxacin Using Metabolomics
Knoll, K. E., Lindeque, J. Z., Adeniji, A. A., Oosthuizen, C. B., Lall, N., & Loots, D. T. (2021) · Microorganisms · doi:10.3390/microorganisms9061158 · Cited by 24
Vijay, S., Nhung, H. N., Bao, N. L. H., Thu, D. D. A., Trieu, L. P. T., Phu, N. H., Thwaites, G. E., Javid, B., & Thương, N. T. T. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01439-20 · Cited by 22
Garcia‐Cremades, M., Solans, B. P., Strydom, N., Vrijens, B., Pillai, G. C., Shaffer, C., Thomas, B. V., & Savić, R. M. (2021) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-041921-074800 · Cited by 22
Determinants of tuberculosis treatment interruption among patients in Vihiga County, Kenya
Wekunda, P. W., Aduda, D. S. O., & Guyah, B. (2021) · PLoS ONE · doi:10.1371/journal.pone.0260669 · Cited by 21
Sharani, Z. Z., Ismail, N. B., Yasin, S. M., Zakaria, Y., Razali, A., Demong, N. A. R., Mohammad, M., & Ismail, Z. (2022) · BMC Public Health · doi:10.1186/s12889-022-13020-3 · Cited by 21
Akpobolokemi, T., Martínez-Nuñez, R. T., & Raimi‐Abraham, B. T. (2022) · The Journal of Medicine Access · doi:10.1177/23992026211070406 · Cited by 20
Stephanie, F., Tambunan, U. S. F., & Siahaan, T. J. (2022) · Life · doi:10.3390/life12111774 · Cited by 19
Sekandi, J. N., Onuoha, N. A., Buregyeya, E., Zalwango, S. K., Kaggwa, P., Nakkonde, D., Kakaire, R., Atuyambe, L. M., Whalen, C. C., & Dobbin, K. K. (2020) · JMIR Research Protocols · doi:10.2196/18029 · Cited by 21
Digital health use in latent tuberculosis infection care: A systematic review
Wong, Y. J., Ng, K. Y., & Lee, S. W. H. (2022) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2022.104687 · Cited by 19
Kay, A. W., Thivalapill, N., Skinner, D. G., Dube, G. S., Dlamini, N., Mzileni, B., Fuentes, P., Ustero, P., Adams, L. V., & Mandalakas, A. M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0243713 · Cited by 18
Jayanti, R. P., Long, N. P., Phat, N. K., Cho, Y., & Shin, J. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14050990 · Cited by 17
As'hab, P. P., Keliat, B. A., & Wardani, I. Y. (2022) · Journal of Public Health Research · doi:10.4081/jphr.2021.2737 · Cited by 16
Dawson, R., Diacon, A. H., Narunsky, K., Jager, V. R. D., Stinson, K. W., Zhang, X., Liu, Y., & Hafkin, J. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01477-22 · Cited by 15
Karat, A. S., Jones, A. S. K., Abubakar, I. I., Campbell, C., Clarke, A. L., Clarke, C. S., Darvell, M., Hill, A. T., Horne, R., Kunst, H., et al. (2021) · Journal of Clinical Tuberculosis and Other Mycobacterial Diseases · doi:10.1016/j.jctube.2021.100233 · Cited by 15
Knoll, K. E., Lindeque, J. Z., Adeniji, A. A., Oosthuizen, C. B., Lall, N., & Loots, D. T. (2021) · Antibiotics · doi:10.3390/antibiotics10060693 · Cited by 15
Islam, F., Ahmad, H., Nurbaya, N., Ahmad, M., Ansar, Ramadhan, K., Syukri, M., Arrazy, S., Perdana, A. A., Siregar, D., et al. (2024) · Journal of Public Health and Pharmacy · doi:10.56338/jphp.v4i1.5022 · Cited by 14
The past, present and future of tuberculosis treatment
Bi, K., Cao, D., Cheng, D. I. N. G., Lu, S., Lu, H., ZHANG, G., Zhang, W., Li, L., Xu, K., Li, L., et al. (2022) · Journal of Zhejiang University (Medical Sciences) · doi:10.3724/zdxbyxb-2022-0454 · Cited by 14
Sekandi, J. N., Buregyeya, E., Zalwango, S. K., Nakkonde, D., Kaggwa, P., Quach, T. H. T., Asiimwe, D., Atuyambe, L. M., & Dobbin, K. K. (2024) · JMIR mhealth and uhealth · doi:10.2196/57991 · Cited by 13
Pietersen, E., Anderson, K., Cox, H. S., Dheda, K. U. J., Bian, A., Shepherd, B. E., Sterling, T. R., Warren, R. M., & van der Heijden, Y. F. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281097 · Cited by 13
Chen, Y., Jiang, Q., Mijiti, P., Takiff, H. E., & Gao, Q. (2023) · eLife · doi:10.7554/elife.84815 · Cited by 13
Digital Technology for Tuberculosis Medication Adherence: Promise and Peril
Haberer, J. E., & Subbaraman, R. (2020) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202001-027ed · Cited by 11
Stagg, H. R., Thompson, J. A., Lipman, M. C. I., Sloan, D. J., Flook, M., & Fielding, K. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202201-0144oc · Cited by 10
Self-citationLee, H., Bea, S., Kim, J. H., Jeong, H. E., Jang, S. H., Son, H., & Shin, J. (2024) · Public Health · doi:10.1016/j.puhe.2024.01.021 · Cited by 10
Unravelling the flexibility of Mycobacterium tuberculosis: an escape way for the bacilli
Sau, S., Roy, A., Agnivesh, P. K., Kumar, S., Guru, S. K., Sharma, S., & Kalia, N. P. (2023) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001695 · Cited by 9
Jones, A. S. K., Bidad, N., Horne, R., Stagg, H. R., Wurie, F. B., Kielmann, K., Karat, A. S., Kunst, H., Campbell, C., Darvell, M., et al. (2021) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.21.0024 · Cited by 9
The use of digital technologies in adherence to anti-tuberculosis treatment
Fielding, K., Subbaraman, R., Khan, A. R., Celan, C., Charalambous, S., Franke, M. F., Huddart, S., Katamba, A., Law, S. J., & Stagg, H. R. (2023) · European Respiratory Society eBooks · doi:10.1183/2312508x.10002223 · Cited by 8
Self-citationÖZALTUN, Ş. C., & Akın, L. (2024) · Healthcare · doi:10.3390/healthcare12232353 · Cited by 8
Wekesa, C., Sekaggya‐Wiltshire, C., Zawedde‐Muyanja, S., Lume, I., Nabaggala, M. S., Parkes-Ratanshi, R. M., & Adakun, S. A. (2023) · Trials · doi:10.1186/s13063-023-07314-z · Cited by 8
Garbrah, B. G., Abebrese, J., & Owusu‐Marfo, J. (2023) · Journal of Public Health · doi:10.1007/s10389-023-02002-3 · Cited by 8
Standards for clinical trials for treating TB
du Cros, P., Greig, J. E., Alffenaar, J.-W. C., Cross, G. B., Cousins, C., Berry, C., Khan, U. A., Phillips, P. P. J., Velásquez, G. E., Furin, J. J., et al. (2023) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.23.0341 · Cited by 9
Arakelyan, S., Karat, A. S., Jones, A. S. K., Vidal, N., Stagg, H. R., Darvell, M., Horne, R., Lipman, M. C. I., & Kielmann, K. (2021) · Patient Preference and Adherence · doi:10.2147/ppa.s313633 · Cited by 8
Law, S. J., Fulcher, I., Ashraf, S., Bastard, M., Docteur, W., Franke, M. F., Guerra, D., Hewison, C., Huerga, H., Khan, M., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf467 · Cited by 7
Zhang, H., Sun, R., Wu, Z., Liu, Y., Chen, M., Huang, J., Lv, Y., Zhao, F., Zhang, Y., Li, M., et al. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1372146 · Cited by 7
An allopurinol adherence tool using plasma oxypurinol concentrations
Smith‐Diaz, N., STOCKER, S. L., Stamp, L. K., Dalbeth, N., Phipps‐Green, A. J., Merriman, T. R., & Wright, D. F. B. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15516 · Cited by 7
Adisa, R., & Durojaye, D. M. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-099559 · Cited by 6
Preventive treatment for latent tuberculosis from Indian perspective
Hashim, Z., Tyagi, R., Singh, G. V., Nath, A., & Kant, S. (2023) · Lung India · doi:10.4103/lungindia.lungindia_336_23 · Cited by 6
Predicting tuberculosis drug efficacy in preclinical and clinical models from in vitro data
Goh, J. J., Patel, A. S., Ngara, B., van Wijk, R. C., Strydom, N., Wang, Q., Van, N., Washington, T. M., Nuermberger, E. L., Aldridge, B. B., et al. (2025) · iScience · doi:10.1016/j.isci.2025.111932 · Cited by 6
Ardizzoni, E., Mulders, W., Fuertes, M. D. D., Հայրապետյան, Ա., Mirzoyan, A., Faqirzai, J., Khachatryan, N., Oganezova, I., Varaine, F., Bastard, M., et al. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01839-24 · Cited by 6
Setyowati, L., & Emil, E. S. (2021) · JI-KES (Jurnal Ilmu Kesehatan) · doi:10.33006/ji-kes.v5i1.224 · Cited by 6
Ngo, D. M., Doan, N. B., Tran, S. N., Hoang, L. B., Nguyen, H. B., & Nguyen, V. D. (2023) · PLoS ONE · doi:10.1371/journal.pone.0284603 · Cited by 6
Adherence to treatment in pulmonary tuberculosis: Rodgers’ evolutionary concept analysis
Prasetyo, Y. A., Thanasilp, S., & Preechawong, S. (2024) · Belitung Nursing Journal · doi:10.33546/bnj.3416 · Cited by 5
Yan, Y., & Bai, X. (2025) · Nursing Open · doi:10.1002/nop2.70242 · Cited by 5
Ragan, E. J., Gill, C. J., Banos, M., Bouton, T. C., Rooney, J. A., Horsburgh, C. R., Warren, R. M., MYERS, B. J., & Jacobson, K. R. (2021) · JMIR Research Protocols · doi:10.2196/24510 · Cited by 5
Rynhoud, L., & Kagee, A. (2024) · Journal of Health Psychology · doi:10.1177/13591053231224124 · Cited by 4
Reis, K., Wolf, A., Perumal, R., Seepamore, B., Guzman, K. J., Ross, J. E., Cheung, Y. K. K., Amico, K. R., Brust, J. C. M., Padayatchi, N., et al. (2024) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000003394 · Cited by 4
Faye, L. M., Hosu, M. C., Dlatu, N., Iruedo, J., & Apalata, T. R. (2025) · Frontiers in Tuberculosis · doi:10.3389/ftubr.2025.1659333 · Cited by 4
Kangongwe, M. H., Mwanza, W., Mwamba, M., Mwenya, J., Muzyamba, J., Mzyece, J., Hamukale, A., Tembo, E., Nsama, D., Chimzizi, R., et al. (2024) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlae122 · Cited by 4
Xie, F., Yao, R., Li, L., Wu, C., Hu, Y., Zhou, Y., Huang, M., Du, J., Zhao, X., Wan, B., et al. (2025) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.70280 · Cited by 3
Saputro, F. B. J., Agushybana, F., & Jati, S. P. (2024) · Contagion Scientific Periodical Journal of Public Health and Coastal Health · doi:10.30829/contagion.v6i1.19711 · Cited by 3
Goh, J. J. N., Wang, Q., Zhang, N., Suárez, N. D. C., Bustion, A. E., Nuermberger, E. L., & Savić, R. M. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00615-24 · Cited by 3
Turyahabwe, S., Ramachandra, S. S., Quraishi, S., Fasih, I., Quraishi, H., Peddapalegani, P., & Ahmad, A. (2025) · PLoS ONE · doi:10.1371/journal.pone.0318174 · Cited by 3
Dey, A., Lahiri, A., Jha, S. S., Sharma, V., Shanmugam, P., & Chakrabartty, A. K. (2021) · Indian Journal of Tuberculosis · doi:10.1016/j.ijtb.2021.06.001 · Cited by 3
Impact of Medication Adherence on Quality of Life in Tuberculosis Patients
Achmad, G. N. V., Husna, R. M., Priyandani, Y., & Zairina, E. (2025) · Research in Clinical Pharmacy · doi:10.59931/rcp.25.0011 · Cited by 2
Eyawo, O., Lyzwinski, L. N., Ugoji, U. C., Pan, S., Sorkpor, S. K., Tawari-Fufeyin, P., & Hogg, R. S. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-089507 · Cited by 3
Non-Adherence Tree Analysis (NATA)—An adherence improvement framework: A COVID-19 case study
Edifor, E. E., Brown, R., Smith, P., & Kossik, R. (2021) · PLoS ONE · doi:10.1371/journal.pone.0247109 · Cited by 3
Validação do aplicativo móvel TBApp para a gestão do autocuidado de pessoas com tuberculose
de Assis, L. B. D. O., da Silva, D. M. G. V., da Silva, J. M., dos Santos, E. R., Pinheiro, J. D. S., Sacramento, D. S., de Oliveira, H. J. H., & Sicsú, A. N. (2024) · Revista Brasileira de Enfermagem · doi:10.1590/0034-7167-2023-0195 · Cited by 2
Burden of Tuberculosis in Western Sudan During the Sudan Armed Conflict
Mohammed, A. K. Y., Humida, E. H. M., Ali, A. M. O., & Ahmed, H. G. (2025) · Cureus · doi:10.7759/cureus.76944 · Cited by 1
Tekpertey, R., & *, A. E. B. (2025) · Cardiology Research and Reports · doi:10.31579/2692-9759/154 · Cited by 1
Steulet, A., Hippner, P., Maraba, N., Jennings, L., Rabothata, I., Mukora, R., Xaba, N., Mchunu, L., Velen, K., Orrell, C., et al. (2026) · BMC Infectious Diseases · doi:10.1186/s12879-025-12304-4 · Cited by 1
Self-citationOelofse, S., Esmail, A., Perumal, T., Swanepoel, J., Meier, S., Mbuthini, L., Jaumdally, S. Z., Scott, A. J., Kühn, L., Pooran, A., et al. (2026) · The Lancet Global Health · doi:10.1016/s2214-109x(25)00489-9 · Cited by 1
Guzman, K. J., Perumal, R., Wolf, A., Lu, X., Boodhram, R., Seepamore, B., Reis, K., Cummings, M. J., Amico, K. R., Cheung, Y. K., et al. (2026) · Annals of Epidemiology · doi:10.1016/j.annepidem.2026.110082 · Cited by 1
Lin, Y., Okibedi, F. U., Karlsson, M. O., & Svensson, E. M. (2026) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70264 · Cited by 1
Ratnasari, D., & Sahrudi, S. (2024) · Indonesian Journal of Global Health Research · doi:10.37287/ijghr.v6i1.2702 · Cited by 1
Rifampicin mono resistant tuberculosis (RR-TB): a case report
Garianto, E., Priyanto, B. A., Aldorino, B. S., Pratiwi, B. R., Lazuardi, B. A., Fattah, B. S., & Octavianda, Y. (2024) · Surabaya Medical Journal · doi:10.59747/smjidisurabaya.v2i1.38 · Cited by 1
Herrera-Olivares, M. Á., Mercado, A. D., Morales-González, R., Pérez-Villanueva, M., Domínguez-Vargas, A., & González-Torres, H. J. (2025) · Infectio · doi:10.22354/24223794.1225 · Cited by 1
PENGARUH PMR DENGAN KARTU PENGINGAT TERHADAP KEPATUHAN DAN KESESUAIAN PENGOBATAN PASIEN TUBERKULOSIS
Universitas Ma Chung, M., & Hendra, G. A. (2020) · Journal of Pharmaceutical Care Anwar Medika · doi:10.36932/jpcam.v3i1.42 · Cited by 1
Titilope, A. A., & Jonathan, D. (2024) · International Journal of Innovative Science and Research Technology (IJISRT) · doi:10.38124/ijisrt/ijisrt24sep576 · Cited by 1
Why do patients not follow therapeutic recommendations?
Jopowicz, A., Piechal, A., & Kurkowska‐Jastrzębska, I. (2021) · Pharmacotherapy in Psychiatry and Neurology · doi:10.33450/fpn.2021.02.002
(2022) · Journal of Social Science and Humanities · doi:10.53469/jssh.2022.4(02).05
John, A., Avirneni, H. T., & Swaminathan, S. S. (2022) · Current Medical Issues · doi:10.4103/cmi.cmi_59_22
Crowninshield, N. (2023) · doi:10.28971/532023cn102
Syamsir, S. B., Permatasari, H., & Setiawan, A. (2023) · PubMed Central · doi:10.30476/ijcbnm.2023.98768.2257
A Case of Pure Red Cell Aplasia as a Possible Complication of Pulmonary Tuberculosis Treatment
Tanuatmadja, A. P., Kwee, L., Tan, F., Sanjaya, A., & Gunadi, J. W. (2023) · Journal Of Medicine & Health · doi:10.28932/jmh.v5i2.6682
Onyenaka, C., Idowu, K. A., Ha, N. P., Graviss, E. A., & Olaleye, O. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417142
Hendra, G. A., Susanto, F. H., & Choirunniza, A. N. (2023) · JIFFK Jurnal Ilmu Farmasi dan Farmasi Klinik · doi:10.31942/jiffk.v20i2.8380
Amoo, O. S., Kareithi, D. N., Tijani, B., Onuigbo, T. I., Karera, S., Oladejo, B., Oraegbu, J. I., Ezike, J., Adekoya, A. M., Sani, M., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4468501/v1
AVALIAÇÃO DE INDICADORES DA ESTRATÉGIA BRASIL LIVRE DA TUBERCULOSE NO MUNICÍPIO DE IMPERATRIZ – MA.
Viana, L. D. R. R., Viana, M. D. R. R., Santos, S. A., & Vale, L. A. S. (2024) · Periódicos Brasil Pesquisa Científica · doi:10.36557/pbpc.v3i2.89
Nur Triningtias, P. (2024) · Bumi · doi:10.61132/bumi.v2i1.63
The pH gradient contributes to persistence in Mycobacterium tuberculosisPreprint
Sherman, D. R., Eldesouky, H. E., Adams, K. N., Brache, J. K., Aguila, L. K. T., Garcia, M., Xing, E., & Li, P. (2025) · Research Square · doi:10.21203/rs.3.rs-7466214/v1
The pH gradient contributes to persistence in Mycobacterium tuberculosisPreprint
Eldesouky, H. E., Adams, K. N., Brache, J. K., Aguila, L. K. T., Garcia, M., Xing, E., Li, P., & Sherman, D. R. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.12.675885
Wekesa, C., Sekaggya‐Wiltshire, C., Muyanja, S. Z., Lume, I., Nabaggala, M. S., Parkes-Ratanshi, R., & Akello, S. A. (2023) · Figshare · doi:10.6084/m9.figshare.22814918
Adisa, R., Ayandokun, T. T., & Ige, O. M. (2021) · Figshare · doi:10.6084/m9.figshare.14385315
Metadata
- Authors
- Vernon, A., Fielding, K., Savic, R., Dodd, L., & Nahid, P.
- Affiliations
- Centers for Disease Control and Prevention (US)
- University of the Witwatersrand (ZA)
- National Institutes of Health (US)
- San Francisco General Hospital (US)
- Corresponding author
- Vernon, Andrew
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2019-12-10
- Volume
- 16
- Issue
- 12
- Pages
- e1002884
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC6903706
- OpenAlex
- W2994185183
- Cited by
- 104
- References
- 35
- Citations by year
- 2026: 6 · 2025: 15 · 2024: 19 · 2023: 23 · 2022: 11 · 2021: 21 · 2020: 9
- FWCI
- 7.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
- Funders
- Centers for Disease Control and Prevention
- Medical Research Council (MR/R010161/1)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Keywords
- tuberculosis, medication adherence, clinical trial design, explanatory trials, pragmatic trials, directly observed therapy, electronic adherence monitoring, drug resistance, pharmacokinetics/pharmacodynamics
- MeSH terms
- Clinical Trials as Topic, Humans, Research Design, Tuberculosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
